October 2021 Volume 17, Issue 10
Volume 17, Issue 10 | October 2021
October 2021
In this Issue
Microbiology
E. coli may hold the key to manufacturing hard-to-make drugs
Scientists combined engineered E. coli with artificial intelligence to produce effective, high-quality protein and antibody-based drugs at a large scale.
Targeting gut bacteria to treat autism
Scientists leverage the gut microbiome-brain connection to develop new treatments for autism spectrum disorders.
Antimicrobial resistance: The silent pandemic
Scientists continue to ring alarm bells about the risks associated with the continued misuse of antimicrobials and advocate for innovative treatments, improved surveillance, and greater public health education.Rare Diseases
Genetic studies of rare undiagnosed diseases take flight with model organisms
Researchers use fruit flies to figure out how genetic mutations disrupt biology and how drugs might reverse these effects.
CRISPR-based muscular dystrophy therapy
An engineer turned biology researcher co-founded a bio-pharma start-up with the goal of using CRISPR to reverse the mutation causing the degenerative muscle disorder Duchenne muscular dystrophy.
Infographic: CRISPR editing for treating Duchenne muscular dystrophy
Researchers are using CRISPR gene editing to restore function of the mutant protein that causes Duchenne muscular dystrophy, a genetic disease that causes muscle degeneration.Cell Biology
Decoding cell behavior and disease with AI and single-cell transcriptomics
Machine learning paired with single-cell analysis helps scientists identify pathways that cause disease and potential therapeutics.
Harnessing cells' own RNA editing tools for new therapeutics
By redirecting cells’ endogenous RNA editing machinery, scientists can correct disease-causing mutations, bringing a new kind of gene therapy to the clinic.
Special report: Live and let die
Researchers redefine cell death in disease and drug discovery.Editor's Insight
